CHIEF: Chinese Hypertension Intervention Efficacy Study

CHIEF was a multicenter randomized controlled clinical trial that compared the efficacy of amlodipine plus angiotensin II receptor blocker with amlodipine plus diuretics on reducing cardiovascular events in high-risk Chinese hypertensive patients aged 50-79. Regimens were titrated to achieve various blood pressure goals that differed for the general population, diabetes, or the elderly. The authors determined that both combination regimens were effective and safe for high-risk hypertensive patients.

• Xingyu Wang, Beijing Hypertension League Institute, Principal Investigator